BPC-157, often referred to as Body Protection Compound-157 , is a synthetic peptide derived from a protective protein found in gastric juice
A 2016 Cochrane Review involving 26 randomized controlled trials and 1,728 patients compared alpha2-agonists including clonidine, lofexidine, guanfacine, and tizanidine with methadone, symptomatic medications, or placebo
We are conveniently located at 19 Summit Square Shopping Center, Langhorne, PA 19047
All mean the same two-compound pair
Rotate injection sites to prevent lipohypertrophy (fat tissue hardening)
Peptide origin / Partial sequence of human gastric protein BPC, isolated from gastric juice Molecular weight / Approximately 1,419 Da (15 amino acids) Common off-label oral dose / 250 to 500 mcg twice daily, taken on an empty stomach Common off-label subcutaneous dose / 200 to 300 mcg once or twice daily near the affected area or abdominally Evidence level / Preclinical only (GRADE: very low certainty for human GI healing) Key preclinical finding / Accelerated gastric ulcer healing in rats within 24 to 72 hours across multiple models Route preference for GI targets / Oral administration, based on topical mucosal contact rationale Safety profile in humans / Largely unknown
